Market Intelligence, Translational Biology, and High-Purity Reagents for TGF-β Superfamily Drug Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GDF11 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GDF11 Recombinant Protein – Mature Domain, Latent Complex (prodomain-complexed), and ECD-Fc variants. High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 expressed (native glycosylation, theoretical MW confirmed). | View GDF11 Products |
| Gene Delivery | GDF11 Lentivirus / ORF Clone – Full-length ORF for stable cell line construction and secretion studies. | View GDF11 Products |
| Benchmark Ab | Anti-GDF11 Monoclonal Antibody (Research Grade) – Recombinant positive control for binding and neutralization assays. Sequence Verified. | View GDF11 Products |
| Validator | GDF11 siRNA Set – For knockdown verification and specificity controls in cell-based assays. | View GDF11 Products |
| Related Target A | GDF8 (Myostatin) – Highly homologous TGF-β family member (~90% mature domain identity); critical selectivity counter-screen. | View GDF8 Products |
| Related Target B | ACVR2B (ActRIIB) – Primary GDF11 receptor; essential for binding and reporter assays; also used in ligand-trap development. | View ACVR2B Products |
| Related Target C | ALK4 (ACVR1B) – Type I receptor component of GDF11 signaling complex. | View ALK4 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GDF11 vs GDF8 Paralog Selectivity | Human, Mouse, Cynomolgus GDF11 and GDF8 ortholog proteins plus GDF11-specific mutant panel; >95% purity; sequence verified by LC-MS/MS for discrimination assays. |
| Species Cross-reactivity (Preclinical) | Ortholog proteins (Human, Cynomolgus, Mouse, Rat) with matched endotoxin specifications (<1 EU/μg). |
| Latent vs Active Conformation Screening | Prodomain-complexed (latent) and furin-cleaved mature (active) GDF11 proteins available; Endotoxin Controlled. |
| Receptor Binding Validation | High-purity GDF11 ligand for SPR/Biacore studies with ActRII receptors; theoretical MW confirmed by SDS-PAGE. |
| Lack of Neutralizing Controls | Research-grade recombinant anti-GDF11 neutralizing antibody included for assay benchmarking. |
| TGF-β Family Off-target Risk | Extended family panel (Activin A, BMP9, TGF-β1) and GDF11 siRNA for orthogonal specificity confirmation. |
| Stability for Subcutaneous Delivery | Endotoxin-controlled, aggregation-tested formulations compatible with high-concentration antibody co-incubation. |
Live GDF11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The GDF11 therapeutic landscape is navigating the “rejuvenation hypothesis” controversy, with emerging clarity on its role in aging-related tissue regeneration. A fundamental biological challenge arises from the ~90% mature-domain homology between GDF11 and GDF8 (Myostatin), making selective pharmacological modulation exceptionally difficult. Early research positioned GDF11 as a potential rejuvenation factor, but recent clinical focus has shifted toward neutralizing abnormal GDF11/GDF8 signaling in neuromuscular and metabolic disorders. As first-generation therapies targeting the broader TGF-β superfamily (e.g., ActRIIB inhibitors) navigate clinical trials, the next wave of R&D is strictly targeting paralog-specific epitopes and latent-complex conformations to unlock either muscle-wasting inhibition or regenerative agonism without systemic cross-reactivity. The field is pivoting toward highly selective modulators rather than pan-ActRII ligands, driving demand for rigorously characterized reagents that can distinguish between these highly similar ligands.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal / Neutralizing Antibody | Novartis, Scholar Rock, Early-stage biotechs | Sarcopenia, Muscle Atrophy, Obesity, Anemia of Chronic Disease | Paralog Selectivity (Need GDF11 vs GDF8 mutant proteins and high-purity homolog panel) |
| Ligand Trap (Receptor-Fc) | Acceleron (Merck), Platform developers targeting ActRII pathway | Cachexia, Metabolic Dysfunction, Pulmonary Arterial Hypertension | Heterodimer Validation & Family Cross-reactivity (Need ACVR2B-Fc + GDF11/GDF8 panel) |
| Recombinant Agonist | Elevian, Regenerative Medicine Consortia | Aging-related decline, Stroke, Heart Failure, CVD | Native Glycosylation & Latent-to-Active Processing (Need HEK293-expressed latent complex and mature protein) |
| Gene Therapy (AAV) | Gene therapy platforms | Aging-related decline | Lentivirus for in vitro validation; Stable cell line construction |